Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom to Raise $51.6M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into an agreement to sell $51.6 million worth of its common stock to unnamed investors in a private placement.

The San Diego-based molecular diagnostics firm said that it will sell 12,435,000 shares of its common stock at a price of $4.15 per share to certain investors. It expects to close the financing on or around May 17.

Sequenom intends to use the funds to continue its R&D efforts and for commercialization of diagnostic tests, as well as for general corporate purposes.

Last week, Sequenom reported its first-quarter financial results and detailed its plans for developing and commercializing its non-invasive Down syndrome test.

It hopes to launch a laboratory-developed test on the market by the end of 2011. It also plans to complete the appropriate studies and documentation necessary to file for premarket approval of the T21 test by the end of 2012.

As of March 31, Sequenom held $29.2 million in cash, and short- and long-term marketable securities.

In early Wednesday trade on the Nasdaq, shares of Sequenom were down nearly 4 percent at $5.18.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.